Fibresolve v3 now available

IMVARIA has released Fibresolve v3, the latest version of its FDA-authorized AI service in ILD and IPF. Fibresolve analyzes a patient's existing chest CT, along with PFTs, age, and sex when available, and provides a qualitative diagnostic classification to serve as an adjunct in the diagnosis of idiopathic pulmonary fibrosis (IPF) prior to invasive testing.

What's new in v3

• Retrained models with architectural enhancements.
• Added Component Contribution Visualization in each report, giving clinicians more transparency into the result.
• Same ordering process. IMVARIA collects the CT images and records, and results go back to the ordering clinician. No contracting, installation, or practice expense.

Fibresolve was authorized by FDA through the De Novo pathway (DEN220040), and v3 was released under its authorized Predetermined Change Control Plan (K252041). Rx only.